Posts by: Iqra Mumal

News

Targeting the interleukin-1β innate immunity pathway through the use of the anti-inflammatory drug canakinumab (ACZ885) led to a significant reduction in lung cancer and lung cancer mortality, new study ... Read more

August 29, 2017August 29, 2017

Novogen to Initiate Phase 2 Clinical Trial of GDC-0084 Therapy for Gliobastoma by Year’s End

News

A Phase 2 trial evaluating Novogen‘s GDC-0084 therapy in glioblastoma patients should begin by year’s end, the Australian company announced. “The GDC-0084 study is on track to commence this year, ... Read more

August 19, 2017

First Patient with BPDCN Receives UCART123 Dose in Phase 1 Clinical Trial

News

The first patient with Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN) has received a dose of Cellectis’ UCART123 in a Phase 1 clinical trial. UCART123 is a gene edited T-cell drug ... Read more

August 18, 2017August 18, 2017

Scientists Examine How Anti-CTLA-4 and Anti-PD-1 Checkpoint-Blockade Therapies Fight Cancer Cells

News

Researchers have known that the checkpoint blockade therapies CTLA-4 and PD-1 inhibitors have been clinically successful in treating cancer patients. But they didn’t fully understand how these inhibitors function. ... Read more

July 22, 2017July 23, 2017

COX-2 Inhibitors May Improve Cancer Immunotherapy Response

News

A new study shows that tumors that constantly express the protein IDO1 (indoleamine 2,3-dioxygenase) are sensitive to COX-2 inhibitors, which may provide an increase in T-cell anti-tumor function. The ... Read more

July 12, 2017

Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies

News

Researchers at Johns Hopkins University have discovered that variations in gene expression levels can provide insight into mechanisms that allow tumors to respond to immunotherapies. The study, “Transcriptional Mechanisms ... Read more

July 5, 2017

EFFECTOR to Work with Pfizer and Merck on Evaluating Colorectal Cancer Immunotherapy Combo

News

EFFECTOR Therapeutics will team up with Pfizer and Merck’s operation in Darmstadt, Germany, to evaluate an immuno-oncology combination theapy in patients with microsatellite stable colorectal cancer. Set to begin in the third quarter of ... Read more

June 29, 2017June 29, 2017

Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy

News

Measuring the blood levels of certain proteins before treatment may help identify patients more likely to benefit from Advaxis‘ immunotherapy vaccine candidate axalimogene filolisbac (axal). In the GOG/NRG-0265 Phase 2 ... Read more